--- title: "Pre-market hot trades in US stocks: CapsoVision pre-market up 7.58%; Zhongchao pre-market down 7.41%" type: "News" locale: "en" url: "https://longbridge.com/en/news/280318354.md" description: "CapsoVision pre-market up 7.58%; Zhongchao pre-market down 7.41%; Paranovus ENT Tech pre-market up 109.25%; ENvue Medical pre-market up 36.36%; AleAnna pre-market up 30.16%" datetime: "2026-03-24T12:42:45.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280318354.md) - [en](https://longbridge.com/en/news/280318354.md) - [zh-HK](https://longbridge.com/zh-HK/news/280318354.md) --- # Pre-market hot trades in US stocks: CapsoVision pre-market up 7.58%; Zhongchao pre-market down 7.41% **Pre-market Hot Trades in US Stocks** CapsoVision is up 7.58% in pre-market trading. Based on recent key news: 1. On March 23, CapsoVision went public on the Nasdaq Capital Market under the ticker CV, with an offering price of $5 per share. The stock performed actively post-listing, reaching a high of $15.37, closing at $6.87, up 11.17%. This performance reflects the market's positive response to its listing. 2. On March 24, CapsoVision showcased its innovative capsule endoscopy platform, emphasizing AI integration and multi-cancer detection capabilities. The company is expanding globally and advancing technological partnerships to enhance its market competitiveness. 3. On March 24, analysts rated CapsoVision as a moderate buy, although some analysts believe that five other stocks offer better investment value. The biotech industry is innovation-driven, with high market attention. Zhongchao is down 7.41% in pre-market trading. Based on recent news: 1. On March 20, the U.S. Securities and Exchange Commission reviewed Zhongchao's financial reports and found potential financial misconduct. This news raised market concerns about the company's financial health, leading to a significant drop in stock price. 2. On March 19, Zhongchao's latest quarterly financial report showed that its revenue and net profit both fell short of market expectations. The report indicated that the company's revenue decreased by 15% year-over-year, and net profit dropped by 20%, further exacerbating investor concerns. 3. On March 18, market rumors suggested that Zhongchao might face intense competition from rivals, increasing market worries about its future profitability. Analysts generally believe that competitive pressure will negatively impact the company's future market share and profitability. The overall performance of the healthcare industry has been weak recently, and investors should exercise caution. **Top Gainers in Pre-market US Stocks** Paranovus is up 109.25% in pre-market trading. Based on recent key news: 1. On March 22, Paranovus terminated its equity distribution agreement with A.G.P./Alliance Global Partners. This move may be interpreted by the market as a strategic adjustment by the company, leading to a significant rise in stock price. Source: Benzinga 2. On March 20, Paranovus appointed Guo Ling as Chief Financial Officer. The addition of new management may have boosted market confidence in the company's future development. Source: Public Technologies 3. On March 20, Paranovus appointed Xu Yijian as a director. This personnel change may be seen as an optimization of the company's governance structure, further boosting investor confidence. Source: Public Technologies The entertainment technology industry has been volatile recently and requires attention. ENvue Medical is up 36.36% in pre-market trading. Based on recent key news: 1. On March 24, ENvue Medical announced the expansion of its presence in major health systems in Michigan, increasing its hospital footprint in the United States to 39. This expansion enhances the company's influence in the healthcare market and drives up its stock price. 2. On March 24, ENvue Medical reported that its ENvue navigation platform and feeding tubes were procured by a 714-bed teaching hospital and Level I trauma center in the Detroit metropolitan area. This order further expands ENvue's deployment in the Southeast Michigan health system, boosting market confidence. 3. In January, ENvue Medical signed a distribution agreement with U-Deliver to distribute its newly launched over-the-counter reusable ENFit syringe product line nationwide through non-acute care channels. This initiative expands the market coverage of the product and supports positive stock performance. The medical device industry has recently performed strongly, supported by policy. AleAnna pre-market rose 30.16%. There has been no significant news recently; trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. no\_news ### Related Stocks - [CV.US](https://longbridge.com/en/quote/CV.US.md) - [ZCMD.US](https://longbridge.com/en/quote/ZCMD.US.md) ## Related News & Research - [CapsoVision Reports First Quarter 2026 Financial Results | CV Stock News](https://longbridge.com/en/news/286459538.md) - [Assessing Dow (DOW) Valuation After Recent Share Price Momentum And Cost Reduction Plans](https://longbridge.com/en/news/286807023.md) - [Is Wall Street Bullish or Bearish on LyondellBasell Stock?](https://longbridge.com/en/news/286902245.md) - [CV Sciences, Inc. Reports First Quarter-End 2026 Financial Results | CVSI Stock News](https://longbridge.com/en/news/286458863.md) - [A Look At PPG Industries (PPG) Valuation After Recent Share Price Weakness](https://longbridge.com/en/news/286654132.md)